Before returning to academia, she co-founded two GPCR-focused biotechs with Heidi Hamm - CUE Biotech and Caden Biosciences - developing G-protein C-terminal mini-gene peptide tools that became widely adopted across Biosciences - allosteric modulator screens and G-protein C-terminal peptide tools 17:17 Current receptors worked in industry, academia and her entrepreneurial side led her to three companies, Cue Biotech , Caden Biosciences , and MyGenomeRx in addition to being a consultant for over a decade.

Scientific Officer and VP of Protein Engineering at Twist Biopharma, the biologics division of Twist Bioscience 01:53 The conversation begins 02:29 From MIT crystallography to leading Twist Biopharma 04:21 Twist Bioscience Aaron Sato from Twist Biopharma , a vertical within Twist Bioscience . During our time together, Aaron and I discussed how using Twist Bioscience’s proprietary technology to Aaron Sato on the web LinkedIn Twitter Google Scholar Twist Bioscience Twist Biopharma Dr.

When Sam Hoare and the CRF receptor team at Neurocrin Biosciences discovered that their lead compound postdoc at the National Institutes of Health studying Class B GPCRs, he spent fifteen years at Neurocrin Biosciences mentorship, and conversations with Nobel laureates 35:38 Into industry: the CRF receptor team at Neurocrin Biosciences Hoare was a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences

Brian Hudson About Brian Hudson Brian is a lecturer in the School of Molecular Biosciences at the University

Riccardo Capelli is an assistant professor in Applied Physics at the Department of Biosciences, University

Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences

Since 2019, Nick has combined his university role with the leadership of Excellerate Bioscience as Chief

Murat Tunaboylu on the web Antiverse DSV Future of Drug Discovery Podcast Twist Bioscience LinkedIn Twitter

Some of my data were also used in an In-vivo study published in iScience, showing the relevance of the

Member‑First — We build what the community needs Execution — Ideas become results through consistent cadence

schedules at 10–15% occupancy, written contracts with every lab member, a Zoom-based communication cadence

That cadence is itself a philosophical statement about who the tool serves.